Loading company
Summit Therapeutics Inc.
SMMT · Nasdaq · ·
Next earnings: October 19, 2026
$16.37+5.6%Sep 29 close
- 1M
- +15.6%
- 6M
- -13.5%
- 1Y
- -20.1%
- 5Y
- +214.1%
SMMT · Nasdaq · ·
Next earnings: October 19, 2026
$16.37+5.6%Sep 29 close
Summit Therapeutics Inc. is scheduled to report next on October 19, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2024, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2024 | 3 months toJun 30, 2023 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$215.7M | -$565.7M | +61.87% |
| Profit per share | -$0.28 | -$0.76 | +63.16% |
| Free Cash Flow | -$142M | -$66.7M | -112.80% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The clinical momentum of ivonescimab continues to build, with two recent key data readouts that significantly bolster our development progress. At ASCO, the landmark HARMONi-6 results established the first head-to-head Phase III study in any tumor type to demonstrate a meaningful overall survival advantage over anti-PD-1 inhibitors in combination with chemotherapy, representing an important milestone for cancer patients and for the broader immuno-oncology field,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol "SMMT"). We are headquartered in Miami, Florida, and we have additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Summit Therapeutics Inc.’s Item 2.02 8-K filed July 23, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Summit Therapeutics Inc. has no earnings call transcript available.